Harbour BioMed is a biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. Its discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery. The company builds its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical-stage asset acquisitions.